SCHEMBL6524288

SCHEMBL6524288

CCN1CCN(c2n[nH]c3cc(Nc4nc(-c5cncc(OC)n5)cc5cc[nH]c(=O)c45)ccc23)CC1

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 17/20 0.69
JAK2 O60674 2/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158109 0.92 ZAP70 (0.63) ZAP70
SCHEMBL12795478 0.86 ZAP70 (0.51) ZAP70JAK2PDGFRBPDGFRA
SCHEMBL1158493 0.86 ZAP70 (0.55) ZAP70JAK2
SCHEMBL1045907 0.84 ZAP70 (0.61) ZAP70
SCHEMBL1049608 0.83 ZAP70 (0.85) ZAP70JAK2
SCHEMBL1158375 0.83 ZAP70 (0.48) ZAP70JAK2PDGFRBPDGFRA
SCHEMBL1158489 0.82 ZAP70 (0.75) ZAP70JAK2
SCHEMBL1049508 0.82 ZAP70 (1.00) ZAP70JAK2
SCHEMBL1158241 0.81 ZAP70 (0.91) ZAP70JAK2
SCHEMBL1158319 0.80 ZAP70 (0.53) ZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN ZAP70 5/4885JAK2 19/4885PDGFRB 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.